Recent Posts in ‘Biotech Stock Profiles’
Pioneers in Regenerative Medicine Reshaping the Landscape of Biotechnology
Every industry or sector has pioneers that worked at the forefront of the field to shepherd new technologies into the mainstream. Oncology, for example, took huge steps forward as a result of the efforts of Dr. Sidney Farber, earning him the titles of “the father of the modern era of chemotherapy” and “father of modern
BioRestorative (BRTX): Two Huge Markets, One Solid Business Model
BioRestorative Therapies Inc. (OTCQB: BRTX), an emerging leader in autologous adult stem cell treatments for the disc/spine, metabolic disorders, and obesity, operating alongside companies like Pluristem Therapeutics Inc. (NASDAQ: PSTI) and Neuralstem Inc. (AMEX: CUR), represents a unique opportunity for investors to capitalize on the industry’s growth. Disc Repair – Non-Surgical Alternative BioRestorative’s primary focus
NeuroMetrix (NURO): An Attractive Diabetes Franchise but Significantly Undervalued
NeuroMetrix Inc. (NASDAQ: NURO), is an innovative medical device company that develops and markets home use and point-of-care devices, associated consumables, and support software for the treatment and management of diabetes and its complications. Diabetes is a worldwide epidemic affecting over 350 million people, including over 25 million people in the United States. The most
Pressure BioSciences (PBIO) Technology In-Depth
Pressure BioSciences, Inc. (OTCQB: PBIO) is a developer of proprietary lab instrumentation and associated consumables based on its game changing Pressure Cycling Technology (PCT), which it provides to companies like Thermo Fisher Scientific (NYSE: TMO), Amgen Inc. (NASDAQ: AMGN) and other medical and biotechnology companies around the world. What is Pressure Cycling Technology? Pressure BioSciences’ Pressure Cycling Technology
Sample Preparation: A Rapidly Growing Industry
Pressure BioSciences Inc. (OTCQB: PBIO), a developer of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology (“PCT”), operating in the same industry as companies like Qiagen NV (NASDAQ: QGEN) and Becton, Dickenson and Co. (NYSE: BDX), recently announced a non-exclusive, worldwide, royalty-bearing license agreement. An Important & Growing Market Sample preparation before
Accelr8 (AXK): Award-Winning Technology Could Unlock Tremendous Value
Accelr8 Technology Corporation (AMEX: AXK), a developer of innovative materials and instrumentation to rapidly identify infectious pathogens, operating in the same basic industry as companies like PolyMedix Inc. (OTCBB: PYMX) and Becton Dickinson and Co. (NYSE: BDX), appears well positioned to unlock significant value over the long-term. Fighting a Common Problem in Hospitals Many people
OxySure Systems (OXYS) Develops the Next “AED” or “Fire Extinguisher”
OxySure Systems Inc. (OTCBB: OXYS), a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions, similar to companies like Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) and ZOLL Medical Corporation (NASDAQ: ZOLL), has developed a product that could become as commonplace as an AED or fire extinguisher in buildings. OxySure
Cytomedix Stands Taller than Competition with New Treatment for Diabetic Foot Ulcers and More
The biotechnology industry is thriving and one of the fastest growing markets available for investment today. Within the industry, the diabetes sector is outpacing most others. In late February, leading business intelligence provider GBI Research released its Diabetes Therapeutics Market to 2017 report. The analysis detailed why the firm sees the global diabetes therapeutic industry
Pressure BioSciences (PBIO): Reading Between the Lines
Pressure BioSciences, Inc. (OTCQB: PBIO), a developer of proprietary lab instrumentation and associated consumables based on its game changing Pressure Cycling Technology (PCT), providing equipment to companies like Thermo Fisher Scientific (NYSE: TMO) and Amgen Inc. (NASDAQ: AMGN), recently announced a very attractive equity financing, when reading between the lines. Above-Market Pricing with Great Terms
CEL-SCI (CVM): A Unique Opportunity in Cancer Treatment
CEL-SCI Corporation (AMEX: CVM), a biotechnology company focused on immunotherapy products for cancer and infectious diseases, similar to companies like ImmunoGen Inc. (NASDAQ: IMGN) and Immunomedics Inc. (NASDAQ: IMMU), represents a misunderstood and highly promising play on head and neck cancer and other diseases. The company’s lead investigational therapy, Multikine® is an immunotherapeutic agent that
Galena Biopharma (GALE): The Next Blockbuster Adjuvant Therapy?
Galena Biopharma Inc. (NASDAQ: GALE), a biopharmaceutical company developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, similar to companies like Roche Holdings Ltd. (PINK: RHHBY), owner of Genentech, and GlaxoSmithKline plc (NYSE: GSK), has developed a promising treatment called NeuVax™ that could significantly change the landscape for adjuvant
Sunshine Biopharma Shares Jump on Multi-Drug Resistant Breast Cancer Presentation News
With the backdrop of news on Monday that Sunshine Biopharma, Inc. (OTCBB:SBFM) will be presenting new scientific data at the American Association for Cancer Research Meeting in Chicago, IL (to be held on March 31 – April 4, 2012), shares of the junior biotech surged a cool 100% to close Monday’s trading at 50 cents